Novo Nordisk has agreed to acquire Cardior Pharmaceuticals, an expert in the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart, for up to $1.12 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved.   Cardior’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patien...